CLINICAL AND PROGNOSTIC VALUE OF PROTEOLYSIS FACTORS IN CHILDREN WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Author:

Bashirova Z. R.1ORCID

Affiliation:

1. Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University, Moscow

Abstract

BACKGROUND. One of the perspectives of modern Nephrology is the study of the mechanisms of nephrosclerosis in ADPKD. Matrix metalloproteinase system (MMP/TIMP)— enzymes that play a key role in the processes of proteolysis in the kidney. THE AIM: to determine the expression of the urine MMP-2, MMP-3 and MMP-9 and their inhibitors TIMP-1 and 2, PAI-I, to establish their relationship with the volume of the kidney corrected to the surface of the body and the functional state of the kidneys, an additional criterion of progression. PATIENTS AND METHODS. The study included 34 children with ADPKD. The level of MMP-2, MMP-3 and MMP-9 and their inhibitors TIMP-1 and 2, PAI-I were determined in urine by ELISA. RESULTS. eGFR in children with total kidney volume greater than 97‰ was significantly lower than in children with normal total kidney volume. In the group of children with a total volume of the kidneys more than 97 percentile,a statistically significant increase in the level of TIMP-1 and TIMP-2 and PAI-I in the urine, and a statistically significant low level of urinary excretion of MMP-3 and MMP-9, compared with the group of children with ADPKD with normal total volume of the kidneys. In the group of children with ADPKD and total kidney volume of more than 97 percentiles of an inverse correlation relationship between the level of eGFR and TIMP-2 and PAI-I, as well as a direct correlation relationship between the total volume of kidney and the urinary excretion of TIMP-1. CONCLUSION. MMP and its inhibitors play an important role in renal damage in children with ADPKD. These proteolysis factors are promising to use as an indicator of the severity of the accumulation of extracellular matrix, that is, monitoring the process of fibrosis, and used as a predictor of progression.

Publisher

Non-profit organization Nephrology

Subject

General Medicine

Reference69 articles.

1. Ong AC, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 2015;385(9981):1993–2002. DOI: 10.1016/ S0140-6736(15)60907-2

2. Wong ATY, Mannix C, Grantham JJ et. al. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 2018 Jan 21;8(1):e018794. DOI: 10.1136/bmjopen-2017-018794

3. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med (1993) 329:332–342. DOI: 10.1056/ NEJM199307293290508

4. He WB, Xiao WJ, Tan YQ et al. Novel mutations of PKD genes in Chinese patients suffering from autosomal dominant polycystic kidney disease and seeking assisted reproduction. J BMC Med Genet 2018 Oct 17;19(1):186. DOI:0.1186/s12881-018-0693-7

5. De Rechter S, Breysem L, Mekahli D. Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder? Front Pediatr 2017;20;5:272. DOI:10.3389/fped.2017.00272

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3